Eltrombopag increases platelet numbers in thrombocytopenic patients with hcv infection and cirrhosis, allowing for effective antiviral therapy

Gastroenterology

Volumn 146, Issue 2, 2014, Pages

  Afdhal, Nezam H ^a   Dusheiko, Geoffrey M ^b   Giannini, Edoardo G ^c   Chen, Pei Jer ^d   Han, Kwang Hyub ^e   Mohsin, Aftab ^f   Rodriguez Torres, Maribel ^g   Rugina, Sorin ^h   Bakulin, Igor ⁱ   Lawitz, Eric ^j   Shiffman, Mitchell L ^k   Tayyab, Ghias Un Nabi ^l   Poordad, Fred ^j   Kamel, Yasser Mostafa ^m   Brainsky, Andres ⁿ   Geib, James ⁿ   Vasey, Sandra Y ⁿ   Patwardhan, Rita ⁿ   Campbell, Fiona M ^m   Theodore, Dickens ⁿ  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Yonsei University College of Medicine   (South Korea)

^f SERVICES HOSPITAL   (Pakistan)

^g Department of Hematology and Oncology   (Puerto Rico)

^h Spitalul Clinic de Boli Infectioase   (Romania)

ⁱ Central Research Institute of Gastroenterology   (Russian Federation)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k Liver Institute of Virginia   (United States)

^l Postgraduate Medical Institute   (Pakistan)

^m GLAXOSMITHKLINE   (United Kingdom)

ⁿ GLAXOSMITHKLINE   (United States)

more..

Author keywords

Blood Clot; Complication; Liver Disease; Portal Hypertension

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ELTROMBOPAG; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CATARACT; CHRONIC LIVER DISEASE; CONTROLLED STUDY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEADACHE; HEMATEMESIS; HEMOGLOBIN BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; LEUKOCYTE COUNT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PANCYTOPENIA; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SUDDEN DEATH; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION; YOUNG ADULT;

ADVERSE EVENT; AE; BLOOD CLOT; CI; COMPLICATION; CONFIDENCE INTERVAL; EARLY VIROLOGIC RESPONSE; ELTROMBOPAG TO INITIATE AND MAINTAIN INTERFERON ANTIVIRAL TREATMENT TO BENEFIT SUBJECTS WITH HEPATITIS C-RELATED LIVER DISEASE; ENABLE; END-OF-TREATMENT RESPONSE; ETR; EVR; HCC; HCV; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; LIVER DISEASE; PATIENT-YEAR; PEG; PEGINTERFERON ALFA; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PVT; PY; RAPID VIROLOGIC RESPONSE; RBV; RIBAVIRIN; RVR; SAE; SERIOUS ADVERSE EVENT; SUSTAINED VIROLOGIC RESPONSE; SVR; TCP; TEE; THROMBOCYTOPENIA; THROMBOEMBOLIC EVENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZOATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC AGENTS; HEPATITIS C, CHRONIC; HUMANS; HYDRAZINES; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; PYRAZOLES; RECOMBINANT PROTEINS; RIBAVIRIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892769466     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.10.012     Document Type: Article

References (22)

1. K.S. Louie, J.M. Micallef, and J.M. Pimenta et al. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review J Viral Hepat 18 2011 1 7
2. M.B. Streiff, S. Mehta, and D.L. Thomas Peripheral blood count abnormalities among patients with hepatitis C in the United States Hepatology 35 2002 947 952
3. E.G. Giannini Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options Aliment Pharmacol Ther 23 2006 1055 1065
4. M. Schmid, A. Kreil, and W. Jessner et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens Gut 54 2005 1014 1020
5. Pegasys (peginterferon alfa-2a). Full prescribing information. South San Francisco, CA: 2011.
6. PegIntron (peginterferon alfa-2b). Full prescribing information. Whitehouse Station, NJ: 2012.
7. M.L. Shiffman, M.G. Ghany, and T.R. Morgan et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C Gastroenterology 132 2007 103 112
8. J.G. McHutchison, M. Manns, and K. Patel et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
9. N. Furusyo, E. Kajiwara, and K. Takahashi et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group J Gastroenterol Hepatol 23 2008 1094 1104
10. J.G. McHutchison, G. Dusheiko, and M.L. Shiffman et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2007 2227 2236
11. M.G. Ghany, D.B. Strader, and D.L. Thomas et al. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
12. DAIDS Division of AIDS table for grading the severity of adult and pediatric adverse events 2004 DAIDS Bethesda, MD
13. C.G. Child, and J.G. Turcotte Surgery and portal hypertension C.G. Child, The liver and portal hypertension 1964 WB Saunders Philadelphia 50 64
14. R.N. Pugh, I.M. Murray-Lyon, and J.L. Dawson et al. Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
15. E.G. Giannini, and N.A. Afdhal Eltrombopag in patients with chronic liver disease Expert Opin Pharmacother 14 2013 669 678
16. E.G. Giannini, M. Basso, and V. Savarino et al. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension J Intern Med 266 2009 537 546
17. A. Iacobellis, M. Siciliano, and B.E. Annicchiarico et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients Aliment Pharmacol Ther 30 2009 146 153
18. J.L. Dienstag, M.G. Ghany, and T.R. Morgan et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C Hepatology 54 2011 396 405
19. V. Ng, and S. Saab Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 2011 923 930
20. B.L. Pearlman Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care Lancet Infect Dis 12 2012 717 728
21. C. Hézode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
22. M.A. Zocco, E. Di Stasio, and R. De Cristofaro et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development J Hepatol 51 2009 682 689